NeuroScientific Biopharmaceuticals (NSB) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition secures full ownership of patented StemSmart technology, expanding innovation in neuroimmune and inflammatory disorder treatments.

• Focus on advancing clinical programs for Crohn's disease and other high-value immune-mediated conditions.

• Diversification into broader disease markets, including GvHD, kidney transplant rejection, and lung disorders.

• Addresses unmet medical needs with alternative treatments for Crohn's disease and GVHD.

Financial terms and conditions

• Market capitalisation post-acquisition is A$26.5 million, with cash on hand of $7.5 million as of June 2025.

• Acquisition completed for 100% of Isopogen WA's issued share capital.

• Performance shares convert upon successful clinical response in special access program for Crohn's fistulas.

• New board appointees receive 5,000,000 unquoted options each, exercisable at $0.07, expiring in 3 years.

Synergies and expected cost savings

• Integration of patented StemSmart process expected to improve efficacy and safety of cell therapies.

• Manufacturing under GMP standards and TGA product license ensures regulatory compliance and quality assurance.